Tirozin Kinaz İnhibitörleri ile Tedavi Edilen Hastalarda Tedavi İzleminde İlaç Etkileşimleri ve Yan Etkilerin Saptanması ve Önlenmesinde Klinik Eczacının Rolü
Üst veriTüm öğe kaydını göster
The use of tyrosine kinase inhibitors as targeted therapies in cancer treatment becomes prevalent. The aim of this study was to determine and prevent drug-drug interactions and also to reduce side effects of thyrosine kinase inhibitors in patients by the involvement of clinical pharmacist in therapeutic monitoring. Fifty five patients using tyrosine kinase inhibitors between October 2015 and April 2016 and followed in the Hacettepe University Hospitals Oncology Hospital, Medical Oncology Department were monitored and evaluated by a clinical pharmacist in terms of drug-drug interactions and side effects. During the study, a total of 92 drug interactions were observed, of those 54 (58,69%) were regarded as clinically significant by a clinical pharmacist. Among those clinically significant drug interactions, pharmacist made recommendations about 18 interactions which were accepted by the doctor and required modifications were implemented where necessary. The side effects of therapies were evaluated at the initial and the second visits by clinical pharmacist, and statistically significant differences were found in severity of side effects related with skin, diarrhea, fatigue and thyroid dysfunction (p<0,005). This study showed that the risks related with drug therapies, particularly with drug interactions and side effects can be reduced by the involvement of clinical pharmacist in multidisciplinary health care team in the treatment of cancer patients.